title: A review of the association between antipsychotic use and hyperprolactinaemia.
abstract: Recent evidence linking hyperprolactinaemia to longer-term clinical sequelae, including osteoporosis, hip fractures and possibly breast cancer, is increasing clinical awareness of the relevance of hyperprolactinaemia. A review of the literature finds clinical trials reporting some degree of comparative prolactin data among antipsychotics. Many of the randomised clinical trials (RCTs) do not report categorical rates of hyperprolactinaemia in contrast with the naturalistic studies, making it complex for clinicians to evaluate the extent and severity of hyperprolactinaemia. Hyperprolactinaemia is one of the commonest adverse events reported in clinical trials and can be found in association with all antipsychotics. The highest rates of hyperprolactinaemia are reported in association with risperidone and amisulpride, often as high as 80-90% of all female subjects and consistently greater than with the typical antipsychotics. Significant rates of hyperprolactinaemia of lesser severity and more transience have also been reported in association with other atypical antipsychotics.
authors.affiliation: Eli Lilly and Company Ltd., Basingstoke, UK. beesbeesbees@blueyonder.co.uk
authors.forename: Chris
authors.initials: C
authors.lastname: Bushe
authors.forename: Michael
authors.initials: M
authors.lastname: Shaw
authors.forename: Robert C
authors.initials: RC
authors.lastname: Peveler
mesh_terms: D014150:Antipsychotic Agents / Q000009:adverse effects*; D002986:Clinical Trials as Topic; D003430:Cross-Sectional Studies; D019317:Evidence-Based Medicine; D005260:Female; D006801:Humans; D006966:Hyperprolactinemia / Q000139:chemically induced* / Q000150:complications; D008297:Male; D001523:Mental Disorders / Q000188:drug therapy*; D012107:Research Design; D018570:Risk Assessment; D012307:Risk Factors
chemical_list: D014150:Antipsychotic Agents